Oral Direct Thrombin Inhibition

This publication has 37 references indexed in Scilit:

• Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
  Journal of Thrombosis and Haemostasis, 2003
• Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug
  Drug Metabolism and Disposition, 2003
• The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model
  Journal of Thrombosis and Haemostasis, 2003
• No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran
  Clinical Pharmacokinetics, 2003
• Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions
  Clinical Pharmacokinetics, 2003
• No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
  Clinical Pharmacokinetics, 2003
• Missed Opportunities for Prevention of Venous Thromboembolism
  Chest, 2001
• Heparin-induced thrombocytopenia
  Blood Reviews, 1999
• Hirudins: Antithrombin Anticoagulants
  Annals of Pharmacotherapy, 1992
• Kinetics of the inhibition of thrombin by hirudin
  Biochemistry, 1986